earnings
confidence high
sentiment positive
materiality 0.75
Krystal Biotech Q2 2026 revenue $119.2M (+24% YoY); net income $54.8M; cash $1.1B
Krystal Biotech, Inc.
2026-Q2 EPS reported
$3.62
revenue$235,579,000
- Q2 2026 VYJUVEK global revenue $119.2M, up 24% YoY; gross margin 95%.
- Net income $54.8M ($1.85 basic EPS) vs $38.3M ($1.33) in Q2 2025.
- Cash and investments $1.1B; FY 2026 non-GAAP R&D+SG&A guidance $175-195M.
- KB803 (ophthalmology) IOLITE study fully enrolled; top-line data expected 4Q 2026.
- KB407 (CF) interim results expected before year end; FDA alignment on registrational study design expected 4Q 2026.